Reduction in Hypoglycemia and No Increase in A1C with Threshold-Based Sensor-Augmented Pump (SAP) Insulin Suspension: ASPIRE In-Home
|
|
- Katherine Hodge
- 6 years ago
- Views:
Transcription
1 Reduction in Hypoglycemia and No Increase in A1C with Threshold-Based Sensor-Augmented Pump (SAP) Insulin Suspension: ASPIRE In-Home Richard M. Bergenstal 1, David C. Klonoff 2, Bruce W. Bode 3, Satish Garg 4, Andrew Ahmann 5, Robert Slover 4, Melissa Meredith 6, Francine R. Kaufman 7, ASPIRE In-Home Study Group Late Breaking Poster 48 Available Saturday June 22 at 10 AM Presented Sunday June 23 at Noon 2PM 1, International Diabetes Center at Park Nicollet, Minneapolis, MN; 2, Mills-Peninsula Health Services, San Mateo, CA; 3, Atlanta Diabetes Associates, Atlanta, GA; 4, Barbara Davis Center for Childhood Diabetes, Aurora, CO; 5, Oregon Health and Sciences University, Portland, OR; 6, University of Wisconsin, Madison, WI; 7, Medtronic, Inc., Northridge, CA
2 Published on June 22, 2013 at NEJM.org N Engl J Med 2013 DOI: /NEJMoa
3 Reducing the Risk of Complications Intensive Glycemic Control in Type 1 Diabetes Rate of Retinopathy (per 100 patient-years) Severe Hypoglycemia (per 100 patient-years) A1C (%) The Diabetes Control and Complications Research Group N Engl J Med 329:977, 1993
4 Bergenstal RM, Tamborlane WV, Ahmann A et al. N Engl J Med. 2010;363: Highlights from the American Diabetes Association 70 th Scientific Sessions l October 2010 l 4
5 STAR 3 Two Therapy Groups Multiple Daily Injections (2 types of insulin) Sensor- Augmented Pump Presented at ADA 2010 and published NEJM 2010
6 STAR 3: A1C at 3, 6, 9, 12 months: All Patients 8.0% 7.3% 8.1% 8.1% 8.0% 7.5% 7.5% 7.5% Values are means ± SE. Asterisks denote P<0.001 for comparisons between SAP group and MDI group at each time point. Adapted from Bergenstal RM, Tamborlane WV, Ahmann A et al. N Engl J Med. 2010;363:
7 Severe Hypoglycemia and A1C DCCT (1993), JDRF (2008), STAR 3 (2010) & ASPIRE in Home (2013) Studies Severe Reaction Every: 1.6 yrs. DCCT (intensive therapy): 62 per 100 pt-yrs, A1C(6.5 yr): 9.0% 7.2% 5 yrs. 7.5 yrs. JDRF CGM (adults, 1 subject excluded): 20.0 per 100 pt-yrs; A1C (6 mo): 7.5% 7.1% STAR 3 MDI (all ages): 13.5 per 100 pt-yrs; A1C (1 yr): 8.3% 8.1% STAR 3 SAP (all ages): 13.3 per 100 pt-yrs; A1C (1 yr): 8.3% 7.5% None Ideal Adapted from Figure 5B of: DCCT. N Engl J Med. 1993;329: JDRF data from: JDRF CGM Study Group. N Engl J Med. 2008;359: Bergenstal RM, Tamborlane WV, Ahmann A, et al. [published online ahead of print June 29, 2010]. N Engl J Med. doi: [].
8 Sensor Augmented Pump (SAP) Sensor Augmented Pump + Threshold Suspend (SAP + TS)
9 Participants Baseline Enrollment (414) Screen failures or withdrawals (94) Run-in Phase (2 weeks) (320) Randomized (247) Threshold Suspend (121) Control (126) Withdrawals or did not meet randomization criteria (73) which included at least one episode of nocturnal hypoglycemia in 2 weeks Early withdrawals (5 Threshold Suspend, 2 Control) Threshold Suspend Control Age 41.6 ± ± 13.8 % Male Diabetes Duration 27.1 ± ± 12.7 BMI, kg/m ± ± 4.3 Study Phase (3 months) A1C and Nocturnal Hypoglycemia AUC
10 Predictors of Nocturnal Hypoglycemia During the Run In Phase of the ASPIRE 2 Study Bruce W. Bode 1, Scott W. Lee 2, Francine R. Kaufman 2, ASPIRE In Home Study Group 1, Atlanta Diabetes Associates, Atlanta, GA; 2, Medtronic, Inc., Northridge, CA Background Results (updated after study completion) Summary In an attempt to mitigate hypoglycemia, particularly that which occurs at night, sensor augmented pump systems have been developed that allow for automatic insulin suspension at a preset sensor glucose threshold (Threshold Suspend, TS, previously referred to as Low Glucose Suspend). Previous studies have shown the benefit of the TS feature in mitigating hypoglycemia. The present study was conducted to examine the safety and efficacy of the TS feature in a randomized, controlled study in which the study patient population was enhanced for nocturnal hypoglycemia. Data from those who completed the run in period of this study were used to examine predictors of hypoglycemia. Methods Screened (414) Entered Run in Phase (2 weeks) (320) Completed Run In Phase (314) Randomized (247) Screen failures or withdrawals (94) Withdrawals and Randomization Failures (73) Patient Characteristics (N=314 patients who completed the Run-In Phase) Age, 43.6 ± years (range, 16-70) Sex, 60.2% female Race, 96.5% white Height, ± 9.76 cm (range, ) Weight, 79.5 ± kg (range, ) BMI, 27.5 ± 4.82 kg/m 2 (range, ) Diabetes duration, 26.9 ± years (range, ) The incidence of NH was higher in patients with lower baseline A1C values and higher glycemic variability (GV). The findings of higher rates of NH in younger patients, patients with shorter diabetes duration, and patients with lower BMI appears to result from greater GV in these patients. Gender and race had no effect on NH. Conclusion The rate of NH events was 0.3 per patient night. The tables show variables examined More than in 3 months association CGM: with 56.7% the mean (±SD) number of NH events per patient per 2 week interval. N, number of NH events in each patient category. The total number of NH events was 314. GV, glycemic variability. A1C at screening visit, 7.6 ± 0.9% (range, ) Baseline A1C N NH Events 7% ± 3.39 > 7% ± 2.66 P value <0.001 P value (adjusted for GV) <0.001 Diabetes Duration N NH Events 15 years ± 3.46 > 15 years ± 2.77 P value < P value (adjusted for GV) 0.82 In an attempt to identify patients potentially most at risk for NH, the use of glycemic variability coupled with A1C might be useful in clinical practice or to define a study cohort at risk. Study Visit Schedule Coefficient of Variation (a measure of glycemic N NH Events variability) 40% ± 2.19 > 40% ± 3.06 P value <0.001 Basal:Bolus Ratio N NH Events Basal Bolus ± 2.95 Basal > Bolus ± 2.95 P value 0.27 P value (adjusted for GV) 0.12 Age N NH Events 50 years ± 2.95 > 50 years ± 2.88 P value P value (adjusted for GV) 0.86 BMI N NH Events < 25 kg/m ± kg/m ± 2.98 P value P value (adjusted for GV) 0.34 Continuous Variable P value P value (adjusted for GV) Baseline A1C <0.001 <0.001 Coefficient of Variation <0.001 N/A Basal:Bolus Ratio Age < Diabetes Duration < BMI There was no effect of gender (P=0.77) or race (P=0.13). See Poster LB 48 for study results. ASPIRE In Home Study Group AMCR Institute, Escondido, CA: T. Bailey; Atlanta Diabetes Associates, Atlanta, GA: B. Bode; Rainier Clinical Research Center, Renton, WA: R. Brazg; Texas Diabetes and Endocrinology, Austin, TX: L. Casaubon; University of Colorado Denver and the Barbara Davis Center, Aurora, CO: S. Garg, R. Slover; Palm Beach Diabetes and Endocrine Specialists, West Palm Beach, FL: B. Horowitz; Diabetes Research Institute Mills Peninsula Health Services, San Mateo, CA: D. Klonoff; Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, ID: D. Liljenquist; Physicians Research Associates, LLC, Lawrenceville, GA: O. Odugbesan; Endocrine Research Solutions, Inc., Roswell, GA: J. Reed; Ohio University Diabetes Center, Athens, OH: F. Schwartz; Arkansas Diabetes Clinic and Research Center, Little Rock, AR: J. Thrasher; Oregon Health and Science University, Portland, OR: A. Ahmann; International Diabetes Center at Park Nicollet, Minneapolis, MN: R. Bergenstal; Iowa Diabetes and Endocrinology Center (IDEC), Des Moines, IA: A. Bhargava; The Naomi Berrie Diabetes Center, Columbia University, New York, NY: R. Goland; The Board of Regents of the University of Wisconsin Madison, Madison, WI: M. Meredith; Joslin Diabetes Center (Syracuse University), Syracuse, NY: R. Weinstock. Presentation Number 984-P Clinical Therapeutics/New Technology Insulin Delivery Systems Sunday, June 23, 2013 Noon 2:00 PM
11 Nocturnal Hypoglycemia (NH) SG < 65 mg/dl for > 20 min. From 10PM to 8AM No patient intervention Each pt > 2 events over 2 wks. Rates NH 0.3 events per pt night Approx 2.1 NH events per patient per wk
12
13
14
15 NH Something We Need to Fix Now Buckingham data published in Kowalski review: DTT
16 16
17 Participants Baseline Enrollment (414) Screen failures or withdrawals (94) Run-in Phase (2 weeks) (320) Randomized (247) Threshold Suspend (121) Control (126) Withdrawals or did not meet randomization criteria (73) which included at least one episode of nocturnal hypoglycemia in 2 weeks Early withdrawals (5 Threshold Suspend, 2 Control) Threshold Suspend Control Age 41.6 ± ± 13.8 % Male Diabetes Duration 27.1 ± ± 12.7 BMI, kg/m ± ± 4.3 Study Phase (3 months) A1C and Nocturnal Hypoglycemia AUC
18 Sensor Augmented Pump (SAP) Sensor Augmented Pump + Threshold Suspend (SAP + TS)
19 Results Reduction in hypoglycemia (duration and severity) in the Threshold Suspend Group AUC (mg/dl min) Mean AUC of Nocturnal Hypoglycemia Events 1547 (2035) 980 (1200) Threshold Suspend 38% reduction p< (1950) Control 1568 (1995) Run-In Phase Study Phase The mean AUC of NH events was 38% lower in the Threshold Suspend Group. SD values are shown in parentheses.
20 Results Reduction in hypoglycemia events in the Threshold Suspend Group Hypoglycemia Events per Patient-Week Events per Patient-Week (1.2) 1.5 (1.0) 32% reduction p< (1.5) 2.2 (1.3) 5.0 (2.8) 3.3 (2.0) 30% reduction p< (3.0) 4.7 (2.7) Run-In Study 0 Threshold Suspend Nocturnal Control Threshold Suspend Control Combined Day and Night Hypoglycemia events were less frequent in the Threshold Suspend Group. SD values are shown in parentheses.
21 Results Characterization of Threshold Suspend events lasting 2 Hours n=1438 Sensor Glucose (mg/dl) Insulin Suspended Time from TS Event Start (min) Mean ± SD of sensor glucose values surrounding 2-hour TS events. The dotted line is at 70 mg/dl.
22 Results No significant between-group difference in A1C 10 A1C A1C (%) = 0.00±0.44 = -0.04±0.42 Randomization 3-month (0.71) 7.24 (0.67) 7.21 (0.77) 7.14 (0.77) 6 Threshold Suspend Control A1C was similar in the two groups. The 95% CI of the difference in A1C (-0.05, 0.15) did not include the non-inferiority limit of 0.4%.
23 Summary The TS feature improves upon SAP therapy by significantly reducing NH. Reduction in mean event AUC. Reduced percentage of time spent with SG values in the hypoglycemic range. Decreased number of NH events per week No deterioration in A1C with TS use. Low risk of severe rebound hyperglycemia following 2-hour TS events. No severe hypoglycemia in TS feature group
24 Conclusion Automating insulin delivery appears to be an effective and safe strategy to reduce hypoglycemia.
25 Severe Hypoglycemia and A1C DCCT (1993), JDRF (2008), STAR 3 (2010) & ASPIRE in Home (2013) Studies Severe Reaction Every: 1.6 yrs. DCCT (intensive therapy): 62 per 100 pt-yrs, A1C(6.5 yr): 9.0% 7.2% 5 yrs. 7.5yrs. 7.7yrs. JDRF CGM (adults, 1 subject excluded): 20.0 per 100 pt-yrs; A1C (6 mo): 7.5% 7.1% STAR 3 MDI (all ages): 13.5 per 100 pt-yrs; A1C (1 yr): 8.3% 8.1% STAR 3 SAP (all ages): 13.3 per 100 pt-yrs; A1C (1 yr): 8.3% 7.5% ASPIRE SAP 13.0 per 100 pt-yrs; A1C (3mo.): 7.2% 7.1% Never Adapted from Figure 5B of: DCCT. N Engl J Med. 1993;329: JDRF data from: JDRF CGM Study Group. N Engl J Med. 2008;359: Bergenstal RM, Tamborlane WV, Ahmann A, et al. [published online ahead of print June 29, 2010]. N Engl J Med. doi: []. ASPIRE SAP + TS 0.0 per 100 pt-yrs; A1C (3mo.): 7.3% 7.2% Future AP system
26 AP Strategy Iterative Increases in Automation Artificial Pancreas presentations at ADA Scientific Sessions 2013 addressing the various strategies of AP development Bergenstal LB 48 Trang, Jones Australia 228 OR Cameron 9 OR Danne 357 OR Buckingham 37 LB Zisser 11OR Nimir, Phillip, Battelino 13OR Finan 10OR Bode 984 P Russell, Nathan, Damiano OR 15 Castle, Ward 14OR Lee, Renard 16OR 26
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Bergenstal RM, Klonoff DC, Garg SK, et al. -based insulin-pump
More informationPREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS)
PREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS) Pathways for Future Treatment and Management of Diabetes H. Peter Chase, MD Carousel of Hope Symposium Beverly Hilton, Beverly
More informationCAROLINAS CHAPTER/AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS Annual Meeting HILTON HEAD ISLAND FRIDAY PRESENTATION
CAROLINAS CHAPTER/AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS 2016 Annual Meeting HILTON HEAD ISLAND FRIDAY PRESENTATION September 9-11, 2016 ~ Sonesta Resort ~ Hilton Head Island, SC This continuing
More informationWhat is a CGM? (Continuous Glucose Monitor) The Bionic Pancreas Is Coming
The Bionic Pancreas Is Coming Montana Diabetes Professional Conference October 23, 2014 H. Peter Chase, MD Professor of Pediatrics University of Colorado Barbara Davis Center Stanford: Bruce Buckingham,
More informationThe In-Clinic Close Loop Experience in the US
The In-Clinic Close Loop Experience in the US Keystone Symposium, Practical Ways to Achieve Targets in Diabetes Care July 14, 2012 Francine Ratner Kaufman, MD Chief Medical Officer, VP Global Medical,
More informationInsulin Pumps and Glucose Sensors in Diabetes Management
Diabetes Update+ 2014 Congress Whistler, British Columbia Friday March 21, 2014ǀ 8:15 8:45 am Insulin Pumps and Glucose Sensors in Diabetes Management Bruce A Perkins MD MPH Division of Endocrinology Associate
More informationMore Than 1 Year of Hybrid Closed Loop in Pediatrics. Gregory P. Forlenza, MD Assistant Professor Barbara Davis Center
More Than 1 Year of Hybrid Closed Loop in Pediatrics Gregory P. Forlenza, MD Assistant Professor Barbara Davis Center Disclosure Dr. Forlenza has served as a consultant for Abbott Diabetes Care and conducts
More informationPresented by Dr. Bruce Perkins, MD MPH Dr. Michael Riddell, PhD
Type 1 Diabetes and Exercise: Optimizing the Medtronic MiniMed Veo Insulin Pump and Continuous Glucose Monitoring (CGM) for Better Glucose Control 1,2 for Healthcare Professionals Presented by Dr. Bruce
More informationDiabetes Management with Continuous Glucose Monitoring & Multiple Daily Injections. Aaron Michels MD
Diabetes Management with Continuous Glucose Monitoring & Multiple Daily Injections Aaron Michels MD Outline SMBG & CGM by age group JDRF CGM Trial Sensor Augmented Insulin Pump Therapy for A1c Reduction
More informationThreshold-Based Insulin-Pump Interruption for Reduction of Hypoglycemia
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Threshold-Based Insulin-Pump Interruption for Reduction of Hypoglycemia Richard M. Bergenstal, M.D., David C. Klonoff, M.D., Satish
More informationDiabetes Management: Current High Tech Innovations
Diabetes Management: Current High Tech Innovations How Far We ve Come in the Last 40 Years William V. Tamborlane, MD Department of Pediatrics Yale School of Medicine Disclosures I am a consultant for:
More informationArtificial Pancreas Device Systems. Populations Interventions Comparators Outcomes. pump. pump
Protocol Artificial Pancreas Device Systems (10130) Medical Benefit Effective Date: 04/01/18 Next Review Date: 01/19 Preauthorization Yes Review Dates: 03/15, 03/16, 03/17, 01/18 Preauthorization is required.
More informationThe Diamond Study: Continuous Glucose Monitoring In Patients on Mulitple Daily Insulin Injections
8/5/217 The Diamond Study: Continuous Glucose Monitoring In Patients on Mulitple Daily Insulin Injections Richard M. Bergenstal, MD Executive Director International Diabetes Center at Park Nicollet Minneapolis,
More informationArtificial Pancreas Device Systems. Populations Interventions Comparators Outcomes Individuals: With type 1 diabetes
Protocol Artificial Pancreas Device Systems Medical Benefit Effective Date: 07/01/18 Next Review Date: 01/20 Preauthorization Yes Review Dates: 03/15, 03/16, 03/17, 01/18, 05/18, 01/19 Preauthorization
More informationGlucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes
DIABETES TECHNOLOGY & THERAPEUTICS Volume 19, Number 3, 2017 Mary Ann Liebert, Inc. DOI: 10.1089/dia.2016.0421 ORIGINAL ARTICLE Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery
More informationArtificial Pancreas Device System (APDS)
Medical Policy Manual Durable Medical Equipment, Policy No. 77 Artificial Pancreas Device System (APDS) Next Review: October 2019 Last Review: October 2018 Effective: November 1, 2018 IMPORTANT REMINDER
More informationUpdate on Continuous Glucose Monitoring (CGM) Technology in Diabetes. Elena Toschi, MD November 12, 2016
Update on Continuous Glucose Monitoring (CGM) Technology in Diabetes Elena Toschi, MD November 12, 2016 Presenter Disclosure Information Elena Toschi, MD No financial disclosure Objectives: Use of CGM
More informationAdvances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier?
Advances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier? Alan B Schorr DO FAAIM FACE www.sugardoc.com abs@sugardoc.com Disclosures
More informationComparing the use of SMBG vs. CGM data to Optimize Glucose Control in T2DM
Comparing the use of SMBG vs. CGM data to Optimize Glucose Control in T2DM For the first time using CGM to assess glucose control achieved in both groups Richard M. Bergenstal, MD International Diabetes
More informationSensor-augmented pump systems provide insulin delivery
DIABETES TECHNOLOGY & THERAPEUTICS Volume 18, Number 10, 2016 Mary Ann Liebert, Inc. DOI: 10.1089/dia.2016.0216 ORIGINAL ARTICLE Effectiveness of Automated Insulin Management Features of the MiniMed c
More informationPreventing Hypoglycemia Using Predictive Alarm Algorithms and Insulin Pump Suspension
DIABETES TECHNOLOGY & THERAPEUTICS Volume 11, Number 2, 29 Mary Ann Liebert, Inc. DOI: 1.189/dia.28.32 Preventing Hypoglycemia Using Predictive Alarm Algorithms and Insulin Pump Suspension Bruce Buckingham,
More informationClinical Value and Evidence of Continuous Glucose Monitoring
Clinical Value and Evidence of Continuous Glucose Monitoring 9402313-012 Objective To review the clinical value and the recent clinical evidence for Professional and Personal CGM Key Points CGM reveals
More informationMedical Policy. MP Artificial Pancreas Device Systems
Medical Policy MP 1.01.30 BCBSA Ref. Policy: 1.01.30 Last Review: 01/30/2018 Effective Date: 04/01/2018 Section: Durable Medical Equipment Related Policies 1.01.20 Continuous or Intermittent Monitoring
More informationArtificial Pancreas Device Systems
Artificial Pancreas Device Systems Policy Number: 1.01.30 Last Review: 1/2019 Origination: 1/2017 Next Review: 1/2020 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for
More informationDiabetes Care 34: , 2011
Clinical Care/Education/Nutrition/Psychosocial Research O R I G I N A L A R T I C L E Use of Continuous Glucose Monitoring in Subjects With Type 1 Diabetes on Multiple Daily Injections Versus Continuous
More informationAdvances Towards the Bionic Pancreas.
Advances Towards the Bionic Pancreas. Ron Brazg MD, FACE Rainier Clinical Research Center Renton, WA DISCLOSURES Rainier Clinical Research Center is an independent research facility not directly affiliated
More informationInsulin Pump Therapy in children. Prof. Abdulmoein Al-Agha, FRCPCH(UK)
Insulin Pump Therapy in children Prof. Abdulmoein Al-Agha, FRCPCH(UK) aagha@kau.edu.sa Highlights Evolution of insulin pump Pumps mimics Pancreas Goals of diabetes care What lowers HbA1c Criteria for selection
More informationDiabetes Care Publish Ahead of Print, published online September 11, 2007
Diabetes Care Publish Ahead of Print, published online September 11, 2007 Slicing the Pie with Continuous Home Monitoring of Glucose: Improved Glycemic Control with Real-life use of Continuous Glucose
More informationJDRF Perspective on Closed Loop
JDRF Perspective on Closed Loop Aaron J. Kowalski, Ph.D. Assistant Vice President Treatment Therapies Juvenile Diabetes Research Foundation International 1 Presenter Disclosure Aaron Kowalski Disclosed
More informationCGM Use in Pregnancy & Unique Populations ELIZABETH O. BUSCHUR, MD THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER
CGM Use in Pregnancy & Unique Populations ELIZABETH O. BUSCHUR, MD THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER Case 1: CGM use during pregnancy 29 yo G1P0000 at 10 5/7 weeks gestation presents to set
More informationControl of Glycemic Variability for Reducing Hypoglycemia Jae Hyeon Kim
Control of Glycemic Variability for Reducing Hypoglycemia Jae Hyeon Kim Division of Endocrinology and Metabolism, Samsung Medical Center, Sungkyunkwan University School of Medicine Conflict of interest
More informationInsulin Delivery and Glucose Monitoring Methods for Diabetes Mellitus: Comparative Effectiveness
Insulin Delivery and Glucose Monitoring Methods for Diabetes Mellitus: Comparative Effectiveness Prepared for: Agency for Healthcare Research and Quality (AHRQ) www.ahrq.gov Outline of Material Introduction
More informationPaolo Di Bartolo U.O di Diabetologia Dip. Malattie Digestive & Metaboliche AULS Prov. di Ravenna. Ipoglicemie e Monitoraggio Glicemico
Paolo Di Bartolo U.O di Diabetologia Dip. Malattie Digestive & Metaboliche AULS Prov. di Ravenna Ipoglicemie e Monitoraggio Glicemico Management of Hypoglycaemia.if hypoglycemia is a problem, the principles
More informationOriginal Article. Nicholas B. Argento, MD 1 ; Katherine Nakamura, PhD 2 ABSTRACT
Original Article Nicholas B. Argento, MD 1 ; Katherine Nakamura, PhD 2 ABSTRACT Objective: Little information is available on personal real-time continuous glucose monitoring (PCGM) in patients 65 years
More informationKing s Research Portal
King s Research Portal DOI: 10.1089/dia.2015.0324 Document Version Publisher's PDF, also known as Version of record Link to publication record in King's Research Portal Citation for published version (APA):
More informationDiabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond)
Diabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond) 9501366-011 20110401 Objectives Understand the need for insulin pumps and CGMS in managing
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Phillip M, Battelino T, Atlas E, et al. Nocturnal glucose control
More informationClinical Policy Title: Artificial pancreas device system
Clinical Policy Title: Artificial pancreas device system Clinical Policy Number: 08.02.07 Effective Date: April 1, 2016 Initial Review Date: November 18, 2015 Most Recent Review Date: February 6, 2018
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Artificial Pancreas Device Systems Page 1 of 16 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Artificial Pancreas Device Systems Professional Institutional Original
More informationThe importance of continuous glucose monitoring when transitioning a patient from insulin detemir to U-500R
Diabetes Management The importance of continuous glucose monitoring when transitioning a patient from insulin detemir to U-500R Connie A Valdez* 1,2, Leah Fitzgerald 1,2 & Sarah Ziherl Hormachea 2 ABSTRACT
More informationInpatient Studies of a Kalman-Filter-Based Predictive Pump Shutoff Algorithm
Journal of Diabetes Science and Technology Volume 6, Issue 5, September 2012 Diabetes Technology Society ORIGINAL ARTICLE Inpatient Studies of a Kalman-Filter-Based Predictive Pump Shutoff Algorithm Fraser,
More informationDiabetes Technology Update. Sarah Konigsberg, MD Diabetes & Endocrine Assoc. April 7, 2018
Diabetes Technology Update Sarah Konigsberg, MD Diabetes & Endocrine Assoc. April 7, 2018 Disclosures None No future technologies are FDA approved Continuous Glucose Monitors Continuous Glucose Monitors
More informationDISCOVER THE POWER OF CONNECTION MINIMED 640G
DISCOVER THE POWER OF CONNECTION MINIMED 640G INSULIN PUMP THERAPY CHANGING LIVES TODAY Have you just been diagnosed with insulin dependent diabetes? Perhaps you ve been on multiple daily injection therapy
More informationWhat is the role of insulin pumps in the modern day care of patients with Type 1 diabetes?
What is the role of insulin pumps in the modern day care of patients with Type 1 diabetes? Dr. Fiona Wotherspoon Consultant in Diabetes and Endocrinology Dorset County Hospital Fiona.Wotherspoon@dchft.nhs.uk
More informationHypoglycemia a barrier to normoglycemia Are long acting analogues and pumps the answer to the barrier??
Hypoglycemia a barrier to normoglycemia Are long acting analogues and pumps the answer to the barrier?? Moshe Phillip Institute of Endocrinology and Diabetes National Center of Childhood Diabetes Schneider
More informationWOULD YOU LIKE MORE CONFIDENCE IN YOUR HYPOGLYCAEMIC CONTROL? SMARTGUARD. PROVIDES PREDICTIVE PROTECTION
WOULD YOU LIKE MORE CONFIDENCE IN YOUR HYPOGLYCAEMIC CONTROL? SMARTGUARD. PROVIDES PREDICTIVE PROTECTION 1,2 MINIMED 640G WITH SMARTGUARD HAVE YOU CONSIDERED THE REAL IMPACT HYPOGLYCAEMIA HAS ON YOUR LIFE?
More informationMedical Education. Personal Continuous Glucose Monitoring Protocol. Innovating for life.
Personal Continuous Glucose Monitoring Protocol A Guide to Continuous Glucose Monitoring Integrated with Insulin Pump Therapy Includes Alert and Trend Management as well as Threshold Medical Education
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Artificial Pancreas Device Systems Page 1 of 15 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Artificial Pancreas Device Systems Professional Institutional Original
More informationTechnology in Diabetes Management Irl B. Hirsch, MD University of Washington
Technology in Diabetes Management 2016 Irl B. Hirsch, MD University of Washington Dualities Research: Helmsley Charitable Trust, JDRF, ADA, NIDDK, CDC Consulting: Abbott, Roche, Intarcia Raise Your Hand
More informationGIVE YOUR PATIENTS CERTAINTY
GIVE CERTAINTY Pictured: The Renouf brothers all live with T1D TECH UPGRADE CGM SUBSCRIPTION INTRODUCING THE TECH UPGRADE CGM SUBSCRIPTION FROM MEDTRONIC HOW SMARTGUARD TM WORKS In Australia people generally
More informationEmerging Automated Insulin Delivery Systems
Emerging Automated Insulin Delivery Systems Richard M. Bergenstal, MD International Diabetes Center Park Nicollet & HealthPartners Minneapolis, MN Presenter Name 1 Dualities: Richard M. Bergenstal, MD
More informationDISCOVER THE POWER OF CONNECTION MINIMED 640G
DISCOVER THE POWER OF CONNECTION MINIMED 640G INSULIN PUMP THERAPY CHANGING LIVES TODAY Has your child just been diagnosed with insulin dependent diabetes? Or perhaps they ve been on multiple daily injection
More informationContinuous Glucose Monitoring (CGM)
Continuous Glucose Monitoring (CGM) Date of Origin: 02/2001 Last Review Date: 07/26/2017 Effective Date: 07/26/2017 Dates Reviewed: 04/2004, 04/2005, 03/2006, 11/2006, 12/2007, 03/2008, 09/2008, 04/2009,
More informationFemale- n (%) 494 (54) White Non-Hispanic 840 (91) Black Non-Hispanic 31 (3) Hispanic 27 (3) Other 21 (2) Age- mean±sd (range) 37.2±18.
Supplementary Table 1. Participant Characteristics Total- n 919 Female- n (%) 494 (54) Race- n (%) White Non-Hispanic 840 (91) Black Non-Hispanic 31 (3) Hispanic 27 (3) Other 21 (2) Age- mean±sd (range)
More informationVIRTUAL PATIENTS DERIVED FROM THE
VIRTUAL PATIENTS DERIVED FROM THE CARELINK DATABASE Benyamin Grosman PhD Senior Principle Scientist Medtronic Diabetes WHY VIRTUAL PATIENT MODELING? Reduce the cost of clinical trials Use models in conjunction
More informationDiabetes Care 34: , with an increased risk of SH. In a
Clinical Care/Education/Nutrition/Psychosocial Research O R I G I N A L A R T I C L E Factors Predictive of Severe Hypoglycemia in Type 1 Diabetes Analysis from the Juvenile Diabetes Research Foundation
More informationFuture Direction of Artificial Pancreas. Roy W. Beck, MD, PhD. JAEB Center for Health Research Tampa, Florida
Future Direction of Artificial Pancreas Roy W. Beck, MD, PhD JAEB Center for Health Research Tampa, Florida Financial Disclosures Dr. Beck does not have any personal conflicts of interest His employer,
More informationHybrid Closed Loop Status & Practical Challenges in Implementation
Hybrid Closed Loop Status & Practical Challenges in Implementation Bruce Buckingham, MD Buckingham@Stanford.edu Professor of Pediatric Endocrinology Stanford School of Medicine Conflict of Interests Company
More informationFlorida Network Symposium
Katrina J. Ruedy, MSPH John W. Lum, MS Jaeb Center for Health Research NE Florida Network Symposium In Conjunction with The 28th Annual Clinical Conference on Diabetes Jaeb Center for Health Research (JCHR)
More informationThe Realities of Technology in Type 1 Diabetes
The Realities of Technology in Type 1 Diabetes May 6, 2017 Rosanna Fiallo-scharer, MD Margaret Frederick, RN Disclosures I have no conflicts of interest to disclose I will discuss some unapproved treatments
More informationReport Reference Guide. THERAPY MANAGEMENT SOFTWARE FOR DIABETES CareLink Report Reference Guide 1
Report Reference Guide THERAPY MANAGEMENT SOFTWARE FOR DIABETES CareLink Report Reference Guide 1 How to use this guide Each type of CareLink report and its components are described in the following sections.
More informationCGM and Closing The Loop
CGM and Closing The Loop Dualities Research: Helmsely Charitable Trust, ADA, JDRF, NIDDK Consulting: Abbott Diabetes Care, Roche, Intarcia, Valeritas, Adocia, Big Foot Like With Pumps, We ve Come A Long
More informationAdvances in Diabetes Care Technologies
Advances in Diabetes Care Technologies 1979 2015 Introduction Roughly 20% to 30% of patients with T1DM and fewer than 1% of insulin-treated patients with T2DM use an insulin pump In 2007, the U.S. FDA
More informationPumps & Sensors made easy. OPADA ALZOHAILI MD FACE Endocrinology Assistant Professor Wayne State University
Pumps & Sensors made easy OPADA ALZOHAILI MD FACE Endocrinology Assistant Professor Wayne State University DeFronzo RA. Diabetes. 2009;58:773-795. Ominous Octet Relationship of b-cell Dysfunction and Development
More informationDIABETES ADVOCATES TAKE ACTION!
DIABETES ADVOCATES TAKE ACTION! TELL CALIFORNIA STATE LEGISLATORS TO SUPPORT AB 447 MEDI-CAL COVERAGE OF CONTINUOUS GLUCOSE MONITORING (CGM) THERAPY FOR HIGH RISK DIABETICS This toolkit provides instructions
More informationDiabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical
Diabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical Practice Guideline Task Force Members Anne Peters, MD (Chair)
More informationSensor-augmented insulin pump with automated low-glucose insulin suspension has the potential to reduce the incidence of major hypoglycemic events.
Research Original Investigation Effect of Sensor-Augmented Insulin Pump Therapy and Automated Insulin Suspension vs Standard Insulin Pump Therapy on Hypoglycemia in Patients With Type 1 Diabetes A Randomized
More informationClinical practice guidelines in management of type 1 diabetic patients
2016 International Conference on Diabetes and Metabolism October 13 ~ 15, 2016, Grand Hilton Seoul Hotel, Korea S2 Behavioral medicine/education : Current management of type 1 diabetes in real clinical
More informationPOLICIES AND PROCEDURE MANUAL
POLICIES AND PROCEDURE MANUAL Policy: MP071 Section: Medical Benefit Policy Subject: Continuous Subcutaneous Glucose Monitor CSGM I. Policy: Continuous Subcutaneous Glucose Monitor (CSGM) II. Purpose/Objective:
More informationCareLink. software REPORT REFERENCE GUIDE. Management Software for Diabetes
CareLink Management Software for Diabetes software REPORT REFERENCE GUIDE How to use this guide Each type of CareLink report and its components are described in the following sections. Report data used
More informationWhen Will CGM Replace SMBG? Roy W. Beck, MD, PhD. JAEB Center for Health Research Tampa, Florida
When Will CGM Replace SMBG? Roy W. Beck, MD, PhD JAEB Center for Health Research Tampa, Florida Financial Disclosures Dr. Beck does not have any personal conflicts of interest His employer, the JAEB Center
More informationClinical Evidence for Insulin Pump Therapy
Clinical Evidence for Insulin Pump Therapy 9501169-011 Objective Review the clinical evidence supporting the use of insulin pump therapy Key Points The benefits of CSII are: Improved metabolic control
More informationDiabetes through my eyes. Rick Mauseth, M.D. W.A.D.E. April 2013
Diabetes through my eyes Rick Mauseth, M.D. W.A.D.E. April 2013 Ant hills Total Available Glucose utilized Two drops of urine in test tube Add 10 drops of water Added tablet Foamed and got hot Compared
More informationArtificial Pancreas Technologies: New Tools to Improve Diabetes Care Today and Tomorrow
Artificial Pancreas Technologies: New Tools to Improve Diabetes Care Today and Tomorrow Mark D. DeBoer, MD, MSc., MCR University of Virginia Center for Diabetes Technologies October 2017 Learning Objectives
More informationDIAGNOSIS OF DIABETES NOW WHAT?
DIAGNOSIS OF DIABETES NOW WHAT? DISCUSS GOALS FOR DIABETES CARE IDENTIFY COMMON COMPLIANCE- ADHERENCE ISSUES DESCRIBE TECHNOLOGY TO ASSIST AND / OR IMPROVE DIABETES CARE WHAT DO WE WANT OUR PATIENTS TO
More informationReduced Hypoglycemia and Increased Time in Target Using Closed-Loop Insulin Delivery During Nights With or Without Antecedent Afternoon Exercise
Clinical Care/Education/Nutrition/Psychosocial Research O R I G I N A L A R T I C L E Reduced Hypoglycemia and Increased Time in Target Using Closed-Loop Insulin Delivery During Nights With or Without
More informationScientific Program As of January 3, Wednesday, 20 February 2019 HALL A7 A2 A3 M1 14:30-16:00
Scientific Program As of January 3, 2019 Plenary Session Parallel Session Oral Presentation Session Industry Session Break Wednesday, 20 February 2019 A7 A2 A3 M1 14:30-16:00 WORKSHOP INDUSTRY SESSION
More informationCGM: Continuous Glucose Monitoring Making Sense of It All AW: ANCO/GEND/1016/0117
CGM: Continuous Glucose Monitoring Making Sense of It All Objectives Review how to do a time effective interpretation of CGM and insulin pump download data Review how medications, lifestyle, and current
More informationEarly Patient and Clinician Experiences with Continuous Glucose Monitoring
Feature Article / Early Experiences with CGM Early Patient and Clinician Experiences with Continuous Glucose Monitoring David K. Bloomgarden, MD, FACE; Janine Freeman, RD, LD, CDE; and Elizabeth DeRobertis,
More informationContinuous or Intermittent Glucose Monitoring in Interstitial Fluid
Continuous or Intermittent Glucose Monitoring in Interstitial Fluid Policy Number: 1.01.20 Last Review: 9/2014 Origination: 11/2001 Next Review: 9/2015 Policy Blue Cross and Blue Shield of Kansas City
More informationThe Impact of Accelerometer Use in Exercise-Associated Hypoglycemia Prevention in Type 1 Diabetes
551045DSTXXX10.1177/1932296814551045Journal of Diabetes Science and TechnologyStenerson et al research-article2014 Original Article The Impact of Accelerometer Use in Exercise-Associated Hypoglycemia Prevention
More informationUNO SGUARDO AL FUTURO. Basta la tecnologia a prevenire l ipoglicemia?
UNO SGUARDO AL FUTURO Basta la tecnologia a prevenire l ipoglicemia? Carmine G. Fanelli MISEM Azienda Ospedaliera Universitaria di Perugia Santa Maria della Misericordia Il sottoscritto dichiara di aver
More informationInnovations in Technology for the Treatment of Diabetes: Clinical Development of the Artificial Pancreas (an Autonomous System)
Journal of Diabetes Science and Technology Volume 5, Issue 3, May 2011 Diabetes Technology Society MEETING PROCEEDINGS Innovations in Technology for the Treatment of Diabetes: Clinical Development of the
More informationWelcome to CareLink Pro
Reference Guide Welcome to CareLink Pro This guide was developed to serve as a reference for obtaining patient data and reviewing CareLink Pro reports. Getting Started with CareLink Pro Adding New Patients
More informationThe Harvard community has made this article openly available. Please share how this access benefits you. Your story matters
Safety and Feasibility of the OmniPod Hybrid Closed-Loop System in Adult, Adolescent, and Pediatric Patients with Type 1 Diabetes Using a Personalized Model Predictive Control Algorithm The Harvard community
More informationUpdate on Diabetes Technology
Update on Diabetes Technology Andrew Ahmann, MD Professor of Medicine Director, Harold Schnitzer Diabetes Health Center OHSU Objectives: Recognize the growing role of technology in assisting patients and
More informationPreliminary Scientific Program As of October 25, Wednesday, 20 February 2019 SYMPOSIUM 16:15-17:45
Preliminary Scientific Program As of October 25, 2018 Plenary Session Parallel Session Oral Presentation Session Industry Session Break Wednesday, 20 February 2019 14:30-16:00 INDUSTRY SYMPOSIUM INDUSTRY
More informationPreliminary Scientific Program As of December 16, Wednesday, 20 February 2019 PARALLEL INDUSTRY SYMPOSIUM 16:15-17:45 18:00-19:00
Preliminary Scientific Program As of December 16, 2018 Plenary Session Parallel Session Oral Presentation Session Industry Session Break Wednesday, 20 February 2019 14:30-16:00 WORKSHOP WORKSHOP SYMPOSIUM
More information15 th Annual DAFNE collaborative meeting Tuesday 28 th June 2016
15 th Annual DAFNE collaborative meeting Tuesday 28 th June 2016 Sponsored by: Abbott Diabetes Care and Lilly Diabetes Type 1 and exercise Royal Berkshire Hospital Centre for Diabetes and Endocrinology
More informationNorbert Hermanns, PhD 1,2, Beatrix Schumann, MD 2, Bernhard Kulzer, PhD 1,2, and Thomas Haak, MD 1,2. Original Article
524105DSTXXX10.1177/1932296814524105Journal of Diabetes Science and TechnologyHermanns et al research-article2014 Original Article The Impact of Continuous Glucose Monitoring on Low Interstitial Glucose
More informationEffective Health Care Program
Comparative Effectiveness Review Number 57 Effective Health Care Program Methods for Insulin Delivery and Glucose Monitoring: Comparative Effectiveness Executive Summary Background Diabetes mellitus is
More informationMicrovascular Disease in Type 1 Diabetes
Microvascular Disease in Type 1 Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine The Course
More informationLessons From The Type 1 Diabetes Exchange
Lessons From The Type 1 Diabetes Exchange Andrew Ahmann, MD Harold Schnitzer Diabetes Health Center at OHSU Presenter Disclosure Information In compliance with the accrediting board policies, the American
More informationContinuous Glucose Monitoring: Changing Diabetes Behavior in Real Time and Retrospectively
Journal of Diabetes Science and Technology Volume 2, Issue 3, May 2008 Diabetes Technology Society CONTROVERSIES in Continuous Glucose Monitoring Continuous Glucose Monitoring: Changing Diabetes Behavior
More informationFaculty of Health Sciences, The University Of Adelaide, Adelaide, South Australia.
The effectiveness of continuous subcutaneous insulin pumps with continuous glucose monitoring in outpatient adolescents with type 1 diabetes: A systematic review Erin Matsuda RN MSN PNP-BC 1 erin.matsuda@samuelmerritt.edu
More informationReport Reference Guide
Report Reference Guide How to use this guide Each type of CareLink report and its components are described in the following sections. Report data used to generate the sample reports was from sample patient
More informationPRELIMINARY SCIENTIFIC PROGRAM As of 29 January Wednesday, 14 February 2018 HALL HALL B HALL L3 HALL M HALL N 14:30-16:00
PRELIMINARY SCIENTIFIC PROGRAM As of 29 January 2018 Plenary session Parallel Session Break Industry Session Oral Presentation Session Ask the speaker feature in App Voting feature in App Wednesday, 14
More information